• Natera entered a strategic collaboration with TransCode Therapeutics to support enrollment in a Phase 2a colorectal cancer trial.
• Signatera MRD testing will be used to identify eligible patients who remain MRD-positive after curative-intent therapy with no radiographic disease.
• Partnership targets faster site-level patient identification to improve enrollment pace for TransCode’s TTX-MC138 study.
• Trial is run by Quantum Leap Healthcare Collaborative’s PRE-I-SPY program, marking its first expansion beyond breast cancer into colorectal cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261013972431) on October 13, 2026, and is solely responsible for the information contained therein.